« Previous AbstractPulmonary function and oxidative stress in workers exposed to styrene in plastic factory: occupational hazards in styrene-exposed plastic factory workers    Next Abstract"Whole-cell response characteristics of ciliated and microvillous olfactory receptor neurons to amino acids, pheromone candidates and urine in rainbow trout" »

Biomolecules

Title:		Pancreatic Cancer Research beyond DNA Mutations
Author(s):		Sato H; Sasaki K; Hara T; Tsuji Y; Arao Y; Otsuka C; Hamano Y; Ogita M; Kobayashi S; di Luccio E; Hirotsu T; Doki Y; Eguchi H; Satoh T; Uchida S; Ishii H;
Address:		"Department of Medical Data Science, Center of Medical Innovation and Translational Research, Osaka University Graduate School of Medicine, Suita, Yamadaoka 2-2, Osaka 565-0871, Japan. Department of Gastrointestinal Surgery, Osaka University Graduate School of Medicine, Suita, Yamadaoka 2-2, Osaka 565-0871, Japan. Hirotsu Bio Science Inc., Chiyoda-Ku, Tokyo 102-0094, Japan. Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Frederikskaj 10B, 2. (Building C), 2450 Copenhagen SV, Denmark"
Journal Title:		Biomolecules
Year:		2022
Volume:		20221017
Issue:		10
Page Number:		-
DOI:		10.3390/biom12101503
ISSN/ISBN:		2218-273X (Electronic) 2218-273X (Linking)
Abstract:		"Pancreatic ductal adenocarcinoma (PDAC) is caused by genetic mutations in four genes: KRAS proto-oncogene and GTPase (KRAS), tumor protein P53 (TP53), cyclin-dependent kinase inhibitor 2A (CDKN2A), and mothers against decapentaplegic homolog 4 (SMAD4), also called the big 4. The changes in tumors are very complex, making their characterization in the early stages challenging. Therefore, the development of innovative therapeutic approaches is desirable. The key to overcoming PDAC is diagnosing it in the early stages. Therefore, recent studies have investigated the multifaced characteristics of PDAC, which includes cancer cell metabolism, mesenchymal cells including cancer-associated fibroblasts and immune cells, and metagenomics, which extend to characterize various biomolecules including RNAs and volatile organic compounds. Various alterations in the KRAS-dependent as well as KRAS-independent pathways are involved in the refractoriness of PDAC. The optimal combination of these new technologies is expected to help treat intractable pancreatic cancer"
Keywords:		"Humans Tumor Suppressor Protein p53/metabolism *Volatile Organic Compounds Proto-Oncogene Proteins p21(ras)/genetics/metabolism *Pancreatic Neoplasms/metabolism *Carcinoma, Pancreatic Ductal/metabolism Mutation DNA/therapeutic use Cyclin-Dependent Kinases;"
Notes:		"MedlineSato, Hiromichi Sasaki, Kazuki Hara, Tomoaki Tsuji, Yoshiko Arao, Yasuko Otsuka, Chihiro Hamano, Yumiko Ogita, Mirei Kobayashi, Shogo di Luccio, Eric Hirotsu, Takaaki Doki, Yuichiro Eguchi, Hidetoshi Satoh, Taroh Uchida, Shizuka Ishii, Hideshi eng Research Support, Non-U.S. Gov't Review Switzerland 2022/10/28 Biomolecules. 2022 Oct 17; 12(10):1503. doi: 10.3390/biom12101503"